Epidermal Growth Factor Receptor (EGFR) Inhibitors in Gastrointestinal Cancer

Publisher： Karger

E-ISSN： 2296-5262|29|3|99-105

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.29, Iss.3, 2006-03, pp. : 99-105

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

MICAL2 promotes breast cancer cell migration by maintaining epidermal growth factor receptor (EGFR) stability and EGFR/P38 signalling activation

By  

ACTA PHYSIOLOGICA (ELECTRONIC), Vol. 222, Iss. 2, 2018-02 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite

The Role of the Epidermal Growth Factor Receptor in Breast Cancer

By Chan Samuel   Hill Mark   Gullick William  

Journal of Mammary Gland Biology and Neoplasia, Vol. 11, Iss. 1, 2006-01 ,pp. : 3-11

Springer Publishing Company

Access to resources Recommend Favorite

The next generation of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of lung cancer

By  

CANCER, Vol. 121, Iss. 8, 2015-04 ,pp. : E1-E6

John Wiley & Sons Inc

Access to resources Recommend Favorite

Management of acquired resistance to epidermal growth factor receptor kinase inhibitors in patients with advanced non‐small cell lung cancer

By  

CANCER, Vol. 120, Iss. 15, 2014-08 ,pp. : 2289-2298

John Wiley & Sons Inc

Access to resources Recommend Favorite

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Advanced Non-Small Cell Lung Cancer

By  

Oncology, Vol. 91, Iss. 1, 2016-07 ,pp. : 26-34

Karger

Access to resources Recommend Favorite